Boston Scientific (NYSE:BSX) Stock Sold by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on September 3rd. The trade occurred in the Representative’s “GABRIELLE ASHTYN HERN TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Boston Scientific Price Performance

Shares of BSX stock opened at $44.10 on Tuesday. The stock has a 50 day moving average price of $46.97 and a 200 day moving average price of $52.24. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm has a market capitalization of $63.92 billion, a P/E ratio of 17.86, a P/E/G ratio of 1.05 and a beta of 0.57.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the company posted $0.75 EPS. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on BSX shares. Piper Sandler restated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Royal Bank Of Canada lowered their price objective on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. BTIG Research dropped their target price on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research note on Wednesday, September 9th. Oppenheimer reduced their target price on shares of Boston Scientific from $85.00 to $65.00 and set an “outperform” rating on the stock in a research report on Monday, September 21st. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $70.19.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward Ludwig acquired 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David Habiger acquired 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Several institutional investors and hedge funds have recently made changes to their positions in BSX. QRG Capital Management Inc. lifted its stake in Boston Scientific by 129.4% in the second quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider’s stock worth $16,031,000 after acquiring an additional 211,855 shares during the period. Andra AP fonden increased its position in Boston Scientific by 13.9% during the 2nd quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider’s stock valued at $8,264,000 after purchasing an additional 23,694 shares during the period. SkyView Investment Advisors LLC purchased a new position in Boston Scientific during the 2nd quarter valued at about $107,000. Bullseye Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $41,000. Finally, Rench Wealth Management Inc. raised its holdings in shares of Boston Scientific by 27.5% in the 2nd quarter. Rench Wealth Management Inc. now owns 27,952 shares of the medical equipment provider’s stock valued at $1,193,000 after purchasing an additional 6,033 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.